Selling stockholders may resell up to 1,692,408 bioAffinity Technologies common shares tied to pre-funded, Series A and Series B warrants. The company would receive no sale proceeds, but cash exercise of all warrants could generate approximately $5.7 million, although exercise timing, amounts and occurrence remain uncertain for investors.

Key Highlights

  • BioAffinity Technologies had 600,736 common shares outstanding before the offering and 2,293,144 assumed afterward.
  • The securities include 564,136 shares tied to each of the pre-funded, Series A and Series B Warrant classes.
  • Warrant exercises are subject to ownership caps of 4.99% or 9.99%, depending on the instrument and holder election.

BioAffinity Technologies, Inc. (NASDAQ: BIAF) is offering a resale framework for selling stockholders covering up to 1,692,408 common shares, with potential company proceeds of approximately $5.7 million if the related warrants are exercised for cash. The shares carry exercise prices of $0.105 per share for the pre-funded warrants and $4.9757 per share for both the Series A and Series B warrants. The company will not receive money from the stock resales themselves, other than warrant exercise payments.

1.69M Shares Tied To Warrants

The resale covers three equal blocks of 564,136 shares. One block may come from pre-funded warrants, another from Series A warrants and the third from Series B warrants. The pre-funded warrants are immediately exercisable at $0.105 per share and remain exercisable until fully exercised. The Series B warrants have a $4.9757 exercise price.

$5.7M Depends On Cash Exercise

Cash exercise of all warrants associated with the 1,692,408 offered shares would produce approximately $5.7 million in gross proceeds for bioAffinity Technologies. That amount is conditional because the company cannot predict whether the warrants will be exercised, when exercises may occur or how many shares will be involved. The company receives no proceeds from sales by the selling stockholders. Its cash inflow is limited to exercise prices paid for common stock issued when the warrants are exercised. The warrants arose from a private Placement agreement dated August 12, 2026, with an institutional investor. The purchase price for each pre-funded warrant was $6.9855, while the Series A and Series B warrants were issued to purchase up to 564,136 shares each.

Ownership And Share Count

BioAffinity Technologies reported 600,736 common shares outstanding before the offering. The assumed post-offering figure is 2,293,144 shares, based on the full issuance of the shares covered by the resale. The assumed figures do not account for exercises of those warrants or options, conversion of the preferred stock or grants from the reserved pool.

Exercise Limits And Timing

The warrants become exercisable following stockholder approval, except that the pre-funded warrants are immediately exercisable. Each warrant expires five years after issuance. The holder cannot exercise a warrant if doing so would result in ownership above 4.99% of outstanding common stock immediately after exercise. That limit may be raised or lowered for the Series A and Series B warrants, with an increase capped at 9.99% and requiring at least 61 days’ advance notice. The pre-funded warrants carry a separate 9.99% ownership ceiling. The placement agent received a cash fee equal to 7.5% of gross proceeds raised in the private placement, along with reimbursement for certain expenses and legal fees.